Developer docs
API playgroundTry for free, no card

Search company profiles

Blueprint

Full company profile

uuid0022ljf

Namestring
Blueprint
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Per the available firmographic record, Blueprint (also referred to as Blueprint Partnership) is a private, for-profit company founded in 2005, headquartered in Manchester, United Kingdom, with 11–50 employees. The firmographic profile characterizes it as a pharmaceutical research agency, though the broader data corpus describes activities consistent with healthcare M&A and real estate advisory under the name 'Blueprint Healthcare Real Estate Advisors.'

The more substantive source data documents the firm as a healthcare-focused M&A and real estate advisory that facilitates the sale of behavioral healthcare businesses and their associated real estate. Its core service is managing complex, combined business-and-real-estate transactions for healthcare entrepreneurs seeking exits, as evidenced by the Parkdale Center engagement in Northwest Indiana, which included partial hospitalization, intensive outpatient, and counseling operations. The firm also serves institutional buyers (e.g., a private equity-backed inpatient and outpatient provider) entering new geographic markets, and has managed competitive sale processes with multiple offers.

The business model is transaction-based advisory, with revenue tied to individual deal closures rather than recurring fees or subscription revenue. Pricing is not publicly disclosed. The firm operates in the United States market based on documented transactions, though its principal office is listed in Manchester, UK — a geographic inconsistency that suggests either cross-border advisory operations or a data-aggregation artifact between two distinct entities sharing the 'Blueprint' name. No technology platform, product suite, or proprietary tooling is documented in the source material.

Short descriptiontext

Blueprint is a private healthcare M&A and real estate advisory firm (operating as Blueprint Healthcare Real Estate Advisors) that facilitates sales of behavioral healthcare businesses and associated real estate, serving healthcare founders seeking exits and private equity-backed buyers entering new markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersManchester, United Kingdom
HQ citystring
Manchester
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
pharmaceutical research, healthcare research, market research services, healthcare M&A advisory, behavioral healthcare transactions
Industry2 codes
PRIMARYHLAIAKAC
Value Dossier & Evidence Generation (AMCP/Global Value Dossier)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
SECONDARYHLAGALAG
Medical Writing & Publications (Clinical/Safety/HEOR)
NAICS code1 code
  • Professional, Scientific, and Technical Services541
Product category
Pharmaceutical Research Services
Social media profiles2 records
Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Firmographic data identifies Blueprint as a pharmaceutical research agency headquartered in Manchester, UK with 11-50 employees and founded in 2005. Documented business activity includes healthcare M&A advisory services through Blueprint Healthcare Real Estate Advisors, facilitating the sale of behavioral healthcare businesses and associated real estate in the US market, including transactions involving both operating businesses and real estate assets.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product information available in the provided source data. The source material describes Blueprint Healthcare Real Estate Advisors as a healthcare real estate advisory firm that facilitates the sale of behavioral healthcare businesses, not a technology product company.

Product and service1 record
1Healthcare M&A and Real Estate Advisory
CategoryHealthcare M&A Advisory
Description

Facilitates the sale of behavioral healthcare businesses and associated real estate assets. Manages competitive sale processes with multiple offers and handles complex transactions involving both operating businesses and real estate. Serves healthcare entrepreneurs seeking exits and PE/strategic buyers seeking market entry.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

A large global healthcare market research and analytics provider operating as part of Kantar. Comparable in pharma research services but operates at much greater scale and with broader syndicated data products.

TypeEmerging player
Description

A newly assembled pharma commercialization advisory platform formed via UDG/Inizio, aggregating market access, medical affairs, and insights capabilities. A growing consolidator and potential competitive threat to independent boutiques.

3Research in Real Life (RiRL)
TypeDirect peer
Description

A pharma market access research firm focused on payer, HTA, and real-world evidence insights. Comparable in market access research positioning and client base.

TypeBroad incumbent
Description

The world's largest life sciences data, technology, and services platform offering market research alongside RWE, clinical, and commercial services. A key scale competitor for pharma research engagements.

5ZS Associates
TypeBroad incumbent
Description

A global consulting firm with a substantial pharmaceutical research and insights practice spanning market access, commercial strategy, and real-world evidence. Comparable in serving pharma commercial teams but at consulting scale.

6The Research Partnership
TypeDirect peer
Description

A London-based boutique pharmaceutical market research agency offering qualitative and quantitative research across therapy areas. Closely comparable to Blueprint in scale, UK base, and dedicated pharma research focus.

TypeDirect peer
Description

A UK-headquartered pharmaceutical market research and business intelligence firm with deep therapy-area expertise. Highly comparable as a boutique pharma research specialist in the UK market.

8SKIM
TypeDirect peer
Description

A specialized market research agency with strong pharma and healthcare practices across pricing, market access, and stakeholder insights. Comparable in boutique positioning and methodology emphasis.

TypeDirect peer
Description

A healthcare-focused research and advisory firm serving pharma clients with insights, evidence, and communications services. Directly comparable in vertical focus and pharma client base.

TypeBroad incumbent
Description

A global CRO and clinical research services firm with an established commercial and market access research practice. Comparable in pharma market access research but embedded in a much broader clinical services portfolio.

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Blueprint

Pharmaceutical Research Servicesblueprintpartnership.com

Blueprint is a private healthcare M&A and real estate advisory firm (operating as Blueprint Healthcare Real Estate Advisors) that facilitates sales of behavioral healthcare businesses and associated real estate, serving healthcare founders seeking exits and private equity-backed buyers entering new markets.

What Blueprint does

Per the available firmographic record, Blueprint (also referred to as Blueprint Partnership) is a private, for-profit company founded in 2005, headquartered in Manchester, United Kingdom, with 11–50 employees. The firmographic profile characterizes it as a pharmaceutical research agency, though the broader data corpus describes activities consistent with healthcare M&A and real estate advisory under the name 'Blueprint Healthcare Real Estate Advisors.'

The more substantive source data documents the firm as a healthcare-focused M&A and real estate advisory that facilitates the sale of behavioral healthcare businesses and their associated real estate. Its core service is managing complex, combined business-and-real-estate transactions for healthcare entrepreneurs seeking exits, as evidenced by the Parkdale Center engagement in Northwest Indiana, which included partial hospitalization, intensive outpatient, and counseling operations. The firm also serves institutional buyers (e.g., a private equity-backed inpatient and outpatient provider) entering new geographic markets, and has managed competitive sale processes with multiple offers.

The business model is transaction-based advisory, with revenue tied to individual deal closures rather than recurring fees or subscription revenue. Pricing is not publicly disclosed. The firm operates in the United States market based on documented transactions, though its principal office is listed in Manchester, UK — a geographic inconsistency that suggests either cross-border advisory operations or a data-aggregation artifact between two distinct entities sharing the 'Blueprint' name. No technology platform, product suite, or proprietary tooling is documented in the source material.

Blueprint firmographics

Firmographics
Name
Blueprint
Website
https://blueprintpartnership.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
Blueprint is a private healthcare M&A and real estate advisory firm (operating as Blueprint Healthcare Real Estate Advisors) that facilitates sales of behavioral healthcare businesses and associated real estate, serving healthcare founders seeking exits and private equity-backed buyers entering new markets.
Ownership category
akta.pro rank

Blueprint industry classification

Industry
Product category
Pharmaceutical Research Services
NAICS
Professional, Scientific, and Technical Services (541)
akta.pro industry
PRIMARYHLAIAKAC
Value Dossier & Evidence Generation (AMCP/Global Value Dossier)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
SECONDARYHLAGALAG
Medical Writing & Publications (Clinical/Safety/HEOR)

Keywords

  • Pharmaceutical research
  • Healthcare research
  • Market research services
  • Healthcare M&A advisory
  • Behavioral healthcare transactions

Where Blueprint is headquartered

Location

Headquarters

HQ city
Manchester
HQ country
United Kingdom
HQ region
Europe

Markets served

Blueprint business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

Blueprint product offering

Product offering

Core offering

Firmographic data identifies Blueprint as a pharmaceutical research agency headquartered in Manchester, UK with 11-50 employees and founded in 2005. Documented business activity includes healthcare M&A advisory services through Blueprint Healthcare Real Estate Advisors, facilitating the sale of behavioral healthcare businesses and associated real estate in the US market, including transactions involving both operating businesses and real estate assets.

Product overview

No product information available in the provided source data. The source material describes Blueprint Healthcare Real Estate Advisors as a healthcare real estate advisory firm that facilitates the sale of behavioral healthcare businesses, not a technology product company.

Differentiator

Problem solved

Functional benefit

Products and services

  • Healthcare M&A and Real Estate Advisory Facilitates the sale of behavioral healthcare businesses and associated real estate assets. Manages competitive sale processes with multiple offers and handles complex transactions involving both operating businesses and real estate. Serves healthcare entrepreneurs seeking exits and PE/strategic buyers seeking market entry.

Companies that use Blueprint

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Blueprint technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Blueprint partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves3 records

Expansion highlights3 records

Blueprint competitors and assessment

Company assessment

Broad incumbents

  • Kantar Health: A large global healthcare market research and analytics provider operating as part of Kantar. Comparable in pharma research services but operates at much greater scale and with broader syndicated data products.
  • IQVIA: The world's largest life sciences data, technology, and services platform offering market research alongside RWE, clinical, and commercial services. A key scale competitor for pharma research engagements.
  • ZS Associates: A global consulting firm with a substantial pharmaceutical research and insights practice spanning market access, commercial strategy, and real-world evidence. Comparable in serving pharma commercial teams but at consulting scale.
  • ICON plc: A global CRO and clinical research services firm with an established commercial and market access research practice. Comparable in pharma market access research but embedded in a much broader clinical services portfolio.

Emerging players

  • Inizio Advisory: A newly assembled pharma commercialization advisory platform formed via UDG/Inizio, aggregating market access, medical affairs, and insights capabilities. A growing consolidator and potential competitive threat to independent boutiques.

Direct peers

  • Research in Real Life (RiRL): A pharma market access research firm focused on payer, HTA, and real-world evidence insights. Comparable in market access research positioning and client base.
  • The Research Partnership: A London-based boutique pharmaceutical market research agency offering qualitative and quantitative research across therapy areas. Closely comparable to Blueprint in scale, UK base, and dedicated pharma research focus.
  • Adelphi Group (Adelphi Research): A UK-headquartered pharmaceutical market research and business intelligence firm with deep therapy-area expertise. Highly comparable as a boutique pharma research specialist in the UK market.
  • SKIM: A specialized market research agency with strong pharma and healthcare practices across pricing, market access, and stakeholder insights. Comparable in boutique positioning and methodology emphasis.
  • Cello Health: A healthcare-focused research and advisory firm serving pharma clients with insights, evidence, and communications services. Directly comparable in vertical focus and pharma client base.

Market position

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

Blueprint social profiles

Digital presence

Blueprint financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Blueprint leadership team

Management profile

Number of profiles

Blueprint funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Blueprint M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blueprint

What does Blueprint do?

Firmographic data identifies Blueprint as a pharmaceutical research agency headquartered in Manchester, UK with 11-50 employees and founded in 2005. Documented business activity includes healthcare M&A advisory services through Blueprint Healthcare Real Estate Advisors, facilitating the sale of behavioral healthcare businesses and associated real estate in the US market, including transactions involving both operating businesses and real estate assets.

When was Blueprint founded?

Blueprint was founded in 2005. It employs 51 to 100 people.

Where is Blueprint based?

Blueprint is headquartered in Manchester, United Kingdom, in the Europe region.

Who are Blueprint's main competitors?

Broad incumbents on record are Kantar Health, IQVIA, ZS Associates and ICON plc. Inizio Advisory is listed as an emerging player. Direct peers are Research in Real Life (RiRL), The Research Partnership, Adelphi Group (Adelphi Research), SKIM and Cello Health.

Does Blueprint have an API?

No public API is recorded for Blueprint.

What industry is Blueprint in?

Blueprint's product category is Pharmaceutical Research Services. Its primary akta.pro industry code is HLAIAKAC, Value Dossier & Evidence Generation (AMCP/Global Value Dossier), with a secondary code of HLAGALAG, Medical Writing & Publications (Clinical/Safety/HEOR). Its NAICS code is 541.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireBlueprint Facilitates Sale of Parkdale Center, a Niche PHP/IOP Behavioral Treatment Business in Northern IndianaBlueprint Healthcare Real Estate Advisors facilitated the sale of Parkdale Center, a behavioral healthcare business specializing in partial hospitalization, intensive outpatient, and counseling services for working professionals in Northwest Indiana, to a private equity-backed inpatient and outpatient provider. The transaction followed a competitive process with multiple offers and included both the operating business and associated real estate, marking the buyer's first entry into the Indiana market. The deal represents a successful exit for the founders after a 10-year entrepreneurial journey and demonstrates Blueprint's expertise in handling complex behavioral healthcare transactions involving both business operations and real estate.Hightimes22 Best Brands of 2022The article reviews notable cannabis brands that defined 2022, recognizing their innovative products and market successes. Companies like Compound Genetics and Blueprint highlighted significant achievements, such as award-winning strains and successful distribution strategies, demonstrating a strong competitive presence in the cannabis industry. The continued growth and community engagement of these brands suggest a promising landscape for the cannabis sector moving forward.PR NewswireGlobal Gastrointestinal Stromal Tumor (GIST) Markets, 2013-2018 & 2018-2026Research and Markets published a market spotlight report on gastrointestinal stromal tumor (GIST), estimating 97,900 incident cases worldwide in 2017, rising to 107,200 by 2026, with incidence rates highest in Asia and lowest in Northern America. The only major licensing deal during 2013-2018 was a $386 million exclusive collaboration between Blueprint and CStone signed in June 2018 to develop and commercialize avapritinib, BLU-554, and BLU-667 in mainland China, Hong Kong, Macau, and Taiwan. Novartis leads in completed clinical trials for GIST with 63 trials, while the majority of industry-sponsored pipeline drugs are in Phase II development.